APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vidarabine Monophosphate for Injection

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vidarabine Monophosphate for Injection Industry Research Report 2026

20 December 2025126 pages

Choose your research edition.

Industry ResearchVidarabine Monophosphate for Injection Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vidarabine Monophosphate for Injection Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vidarabine Monophosphate for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vidarabine Monophosphate for Injection Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Vidarabine Monophosphate for Injection Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vidarabine Monophosphate for Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vidarabine Monophosphate for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vidarabine Monophosphate for Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vidarabine Monophosphate for Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vidarabine Monophosphate for Injection include Wuhan Hualong Biology Pharmacy, Reyoung Pharmaceutical, Kaifeng Mingren Pharmaceutical, China Res Double-Crane, Hainan Jinrui Pharmaceutical, Hainan Huluwa Pharmaceutical Group, Haikou Qili Pharmaceutical, Sinopharm A-think Pharmaceutical and Guangdong Xianqiang Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vidarabine Monophosphate for Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vidarabine Monophosphate for Injection Market by Company

Wuhan Hualong Biology Pharmacy

Reyoung Pharmaceutical

Kaifeng Mingren Pharmaceutical

China Res Double-Crane

Hainan Jinrui Pharmaceutical

Hainan Huluwa Pharmaceutical Group

Haikou Qili Pharmaceutical

Sinopharm A-think Pharmaceutical

Guangdong Xianqiang Pharmaceutical

Guangdong LongFu Medicine

Gansu Changee Bio-pharmaceutical

FUREN Group Pharmaceutical

Datong Wuzhou Tong Pharmaceutical

Vidarabine Monophosphate for Injection Segment by Type

0.1 g/bottle

0.2 g/bottle

Vidarabine Monophosphate for Injection Segment by Application

Hospital

Clinics

Other

Vidarabine Monophosphate for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vidarabine Monophosphate for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vidarabine Monophosphate for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vidarabine Monophosphate for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vidarabine Monophosphate for Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vidarabine Monophosphate for Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vidarabine Monophosphate for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vidarabine Monophosphate for Injection Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Vidarabine Monophosphate for Injection Sales (k units) of Manufacturers (2021-2026) Table 7. Global Vidarabine Monophosphate for Injection Sales Market Share by Manufacturers (2021-2026) Table 8. Global Vidarabine Monophosphate for Injection Revenue of Manufacturers (2021-2026) Table 9. Global Vidarabine Monophosphate for Injection Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Vidarabine Monophosphate for Injection Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Vidarabine Monophosphate for Injection Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Vidarabine Monophosphate for Injection, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Vidarabine Monophosphate for Injection, Product Type & Application Table 14. Global Vidarabine Monophosphate for Injection Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Vidarabine Monophosphate for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Wuhan Hualong Biology Pharmacy Company Information Table 19. Wuhan Hualong Biology Pharmacy Business Overview Table 20. Wuhan Hualong Biology Pharmacy Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Wuhan Hualong Biology Pharmacy Vidarabine Monophosphate for Injection Product Portfolio Table 22. Wuhan Hualong Biology Pharmacy Recent Developments Table 23. Reyoung Pharmaceutical Company Information Table 24. Reyoung Pharmaceutical Business Overview Table 25. Reyoung Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Reyoung Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 27. Reyoung Pharmaceutical Recent Developments Table 28. Kaifeng Mingren Pharmaceutical Company Information Table 29. Kaifeng Mingren Pharmaceutical Business Overview Table 30. Kaifeng Mingren Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Kaifeng Mingren Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 32. Kaifeng Mingren Pharmaceutical Recent Developments Table 33. China Res Double-Crane Company Information Table 34. China Res Double-Crane Business Overview Table 35. China Res Double-Crane Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. China Res Double-Crane Vidarabine Monophosphate for Injection Product Portfolio Table 37. China Res Double-Crane Recent Developments Table 38. Hainan Jinrui Pharmaceutical Company Information Table 39. Hainan Jinrui Pharmaceutical Business Overview Table 40. Hainan Jinrui Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Hainan Jinrui Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 42. Hainan Jinrui Pharmaceutical Recent Developments Table 43. Hainan Huluwa Pharmaceutical Group Company Information Table 44. Hainan Huluwa Pharmaceutical Group Business Overview Table 45. Hainan Huluwa Pharmaceutical Group Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Hainan Huluwa Pharmaceutical Group Vidarabine Monophosphate for Injection Product Portfolio Table 47. Hainan Huluwa Pharmaceutical Group Recent Developments Table 48. Haikou Qili Pharmaceutical Company Information Table 49. Haikou Qili Pharmaceutical Business Overview Table 50. Haikou Qili Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Haikou Qili Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 52. Haikou Qili Pharmaceutical Recent Developments Table 53. Sinopharm A-think Pharmaceutical Company Information Table 54. Sinopharm A-think Pharmaceutical Business Overview Table 55. Sinopharm A-think Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Sinopharm A-think Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 57. Sinopharm A-think Pharmaceutical Recent Developments Table 58. Guangdong Xianqiang Pharmaceutical Company Information Table 59. Guangdong Xianqiang Pharmaceutical Business Overview Table 60. Guangdong Xianqiang Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Guangdong Xianqiang Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 62. Guangdong Xianqiang Pharmaceutical Recent Developments Table 63. Guangdong LongFu Medicine Company Information Table 64. Guangdong LongFu Medicine Business Overview Table 65. Guangdong LongFu Medicine Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Guangdong LongFu Medicine Vidarabine Monophosphate for Injection Product Portfolio Table 67. Guangdong LongFu Medicine Recent Developments Table 68. Gansu Changee Bio-pharmaceutical Company Information Table 69. Gansu Changee Bio-pharmaceutical Business Overview Table 70. Gansu Changee Bio-pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Gansu Changee Bio-pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 72. Gansu Changee Bio-pharmaceutical Recent Developments Table 73. FUREN Group Pharmaceutical Company Information Table 74. FUREN Group Pharmaceutical Business Overview Table 75. FUREN Group Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. FUREN Group Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 77. FUREN Group Pharmaceutical Recent Developments Table 78. Datong Wuzhou Tong Pharmaceutical Company Information Table 79. Datong Wuzhou Tong Pharmaceutical Business Overview Table 80. Datong Wuzhou Tong Pharmaceutical Vidarabine Monophosphate for Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Datong Wuzhou Tong Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio Table 82. Datong Wuzhou Tong Pharmaceutical Recent Developments Table 83. Global Vidarabine Monophosphate for Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Vidarabine Monophosphate for Injection Sales by Region (2021-2026) & (k units) Table 85. Global Vidarabine Monophosphate for Injection Sales Market Share by Region (2021-2026) Table 86. Global Vidarabine Monophosphate for Injection Sales by Region (2027-2032) & (k units) Table 87. Global Vidarabine Monophosphate for Injection Sales Market Share by Region (2027-2032) Table 88. Global Vidarabine Monophosphate for Injection Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Vidarabine Monophosphate for Injection Revenue Market Share by Region (2021-2026) Table 90. Global Vidarabine Monophosphate for Injection Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Vidarabine Monophosphate for Injection Revenue Market Share by Region (2027-2032) Table 92. North America Vidarabine Monophosphate for Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Vidarabine Monophosphate for Injection Sales by Country (2021-2026) & (k units) Table 94. North America Vidarabine Monophosphate for Injection Sales by Country (2027-2032) & (k units) Table 95. North America Vidarabine Monophosphate for Injection Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Vidarabine Monophosphate for Injection Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Vidarabine Monophosphate for Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Vidarabine Monophosphate for Injection Sales by Country (2021-2026) & (k units) Table 99. Europe Vidarabine Monophosphate for Injection Sales by Country (2027-2032) & (k units) Table 100. Europe Vidarabine Monophosphate for Injection Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Vidarabine Monophosphate for Injection Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Vidarabine Monophosphate for Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Vidarabine Monophosphate for Injection Sales by Country (2021-2026) & (k units) Table 104. Asia Pacific Vidarabine Monophosphate for Injection Sales by Country (2027-2032) & (k units) Table 105. Asia Pacific Vidarabine Monophosphate for Injection Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Vidarabine Monophosphate for Injection Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Vidarabine Monophosphate for Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Vidarabine Monophosphate for Injection Sales by Country (2021-2026) & (k units) Table 109. South America Vidarabine Monophosphate for Injection Sales by Country (2027-2032) & (k units) Table 110. South America Vidarabine Monophosphate for Injection Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Vidarabine Monophosphate for Injection Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Vidarabine Monophosphate for Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Vidarabine Monophosphate for Injection Sales by Country (2021-2026) & (k units) Table 114. Middle East and Africa Vidarabine Monophosphate for Injection Sales by Country (2027-2032) & (k units) Table 115. Middle East and Africa Vidarabine Monophosphate for Injection Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Vidarabine Monophosphate for Injection Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Vidarabine Monophosphate for Injection Sales by Type (2021-2026) & (k units) Table 118. Global Vidarabine Monophosphate for Injection Sales by Type (2027-2032) & (k units) Table 119. Global Vidarabine Monophosphate for Injection Sales Market Share by Type (2021-2026) Table 120. Global Vidarabine Monophosphate for Injection Sales Market Share by Type (2027-2032) Table 121. Global Vidarabine Monophosphate for Injection Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Vidarabine Monophosphate for Injection Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Vidarabine Monophosphate for Injection Revenue Market Share by Type (2021-2026) Table 124. Global Vidarabine Monophosphate for Injection Revenue Market Share by Type (2027-2032) Table 125. Global Vidarabine Monophosphate for Injection Price by Type (2021-2026) & (US$/unit) Table 126. Global Vidarabine Monophosphate for Injection Price by Type (2027-2032) & (US$/unit) Table 127. Global Vidarabine Monophosphate for Injection Sales by Application (2021-2026) & (k units) Table 128. Global Vidarabine Monophosphate for Injection Sales by Application (2027-2032) & (k units) Table 129. Global Vidarabine Monophosphate for Injection Sales Market Share by Application (2021-2026) Table 130. Global Vidarabine Monophosphate for Injection Sales Market Share by Application (2027-2032) Table 131. Global Vidarabine Monophosphate for Injection Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Vidarabine Monophosphate for Injection Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Vidarabine Monophosphate for Injection Revenue Market Share by Application (2021-2026) Table 134. Global Vidarabine Monophosphate for Injection Revenue Market Share by Application (2027-2032) Table 135. Global Vidarabine Monophosphate for Injection Price by Application (2021-2026) & (US$/unit) Table 136. Global Vidarabine Monophosphate for Injection Price by Application (2027-2032) & (US$/unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Vidarabine Monophosphate for Injection Distributors List Table 140. Vidarabine Monophosphate for Injection Customers List Table 141. Vidarabine Monophosphate for Injection Industry Trends Table 142. Vidarabine Monophosphate for Injection Industry Drivers Table 143. Vidarabine Monophosphate for Injection Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vidarabine Monophosphate for Injection Product Image Figure 5. Global Vidarabine Monophosphate for Injection Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Vidarabine Monophosphate for Injection Market Size (2021-2032) & (US$ Million) Figure 7. Global Vidarabine Monophosphate for Injection Sales (2021-2032) & (k units) Figure 8. Global Vidarabine Monophosphate for Injection Average Price (US$/unit) & (2021-2032) Figure 9. 0.1 g/bottle Product Image Figure 10. 0.2 g/bottle Product Image Figure 11. Hospital Product Image Figure 12. Clinics Product Image Figure 13. Other Product Image Figure 14. Global Vidarabine Monophosphate for Injection Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Vidarabine Monophosphate for Injection, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Vidarabine Monophosphate for Injection Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Vidarabine Monophosphate for Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Vidarabine Monophosphate for Injection Sales by Region in 2025 Figure 20. Global Vidarabine Monophosphate for Injection Revenue by Region in 2025 Figure 21. North America Vidarabine Monophosphate for Injection Market Size by Country in 2025 Figure 22. North America Vidarabine Monophosphate for Injection Sales Market Share by Country (2021-2032) Figure 23. North America Vidarabine Monophosphate for Injection Revenue Market Share by Country (2021-2032) Figure 24. United States Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Vidarabine Monophosphate for Injection Market Size by Country in 2025 Figure 28. Europe Vidarabine Monophosphate for Injection Sales Market Share by Country (2021-2032) Figure 29. Europe Vidarabine Monophosphate for Injection Revenue Market Share by Country (2021-2032) Figure 30. Germany Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Vidarabine Monophosphate for Injection Market Size by Country in 2025 Figure 41. Asia Pacific Vidarabine Monophosphate for Injection Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Vidarabine Monophosphate for Injection Revenue Market Share by Country (2021-2032) Figure 43. China Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Vidarabine Monophosphate for Injection Market Size by Country in 2025 Figure 52. South America Vidarabine Monophosphate for Injection Sales Market Share by Country (2021-2032) Figure 53. South America Vidarabine Monophosphate for Injection Revenue Market Share by Country (2021-2032) Figure 54. Brazil Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Vidarabine Monophosphate for Injection Market Size by Country in 2025 Figure 58. Middle East and Africa Vidarabine Monophosphate for Injection Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Vidarabine Monophosphate for Injection Revenue Market Share by Country (2021-2032) Figure 60. Egypt Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Vidarabine Monophosphate for Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Vidarabine Monophosphate for Injection Sales Market Share by Type (2021-2032) Figure 66. Global Vidarabine Monophosphate for Injection Revenue Market Share by Type (2021-2032) Figure 67. Global Vidarabine Monophosphate for Injection Price (US$/unit) by Type (2021-2032) Figure 68. Global Vidarabine Monophosphate for Injection Sales Market Share by Application (2021-2032) Figure 69. Global Vidarabine Monophosphate for Injection Revenue Market Share by Application (2021-2032) Figure 70. Global Vidarabine Monophosphate for Injection Price (US$/unit) by Application (2021-2032) Figure 71. Vidarabine Monophosphate for Injection Value Chain Figure 72. Vidarabine Monophosphate for Injection Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Vidarabine Monophosphate for Injection Industry Opportunities and Challenges

Scope & coverage.

Types
  • 0.1 g/bottle
  • 0.2 g/bottle
Applications
  • Hospital
  • Clinics
  • Other
Companies covered
  • Wuhan Hualong Biology Pharmacy
  • Reyoung Pharmaceutical
  • Kaifeng Mingren Pharmaceutical
  • China Res Double-Crane
  • Hainan Jinrui Pharmaceutical
  • Hainan Huluwa Pharmaceutical Group
  • Haikou Qili Pharmaceutical
  • Sinopharm A-think Pharmaceutical
  • Guangdong Xianqiang Pharmaceutical
  • Guangdong LongFu Medicine
  • Gansu Changee Bio-pharmaceutical
  • FUREN Group Pharmaceutical
  • Datong Wuzhou Tong Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Vidarabine Monophosphate for Injection Market Size (2021-2032)
  4. 2.2.2 Global Vidarabine Monophosphate for Injection Sales (2021-2032)
  5. 2.2.3 Global Vidarabine Monophosphate for Injection Market Average Price (2021-2032)
  6. 2.3 Vidarabine Monophosphate for Injection by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 0.1 g/bottle
  9. 2.3.3 0.2 g/bottle
  10. 2.4 Vidarabine Monophosphate for Injection by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinics
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vidarabine Monophosphate for Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Vidarabine Monophosphate for Injection Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Vidarabine Monophosphate for Injection Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Vidarabine Monophosphate for Injection Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Vidarabine Monophosphate for Injection Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Vidarabine Monophosphate for Injection, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Vidarabine Monophosphate for Injection, Product Type & Application
  8. 3.8 Global Manufacturers of Vidarabine Monophosphate for Injection, Established Date
  9. 3.9 Global Vidarabine Monophosphate for Injection Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Wuhan Hualong Biology Pharmacy
  2. 4.1.1 Wuhan Hualong Biology Pharmacy Company Information
  3. 4.1.2 Wuhan Hualong Biology Pharmacy Business Overview
  4. 4.1.3 Wuhan Hualong Biology Pharmacy Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Wuhan Hualong Biology Pharmacy Vidarabine Monophosphate for Injection Product Portfolio
  6. 4.1.5 Wuhan Hualong Biology Pharmacy Recent Developments
  7. 4.2 Reyoung Pharmaceutical
  8. 4.2.1 Reyoung Pharmaceutical Company Information
  9. 4.2.2 Reyoung Pharmaceutical Business Overview
  10. 4.2.3 Reyoung Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Reyoung Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  12. 4.2.5 Reyoung Pharmaceutical Recent Developments
  13. 4.3 Kaifeng Mingren Pharmaceutical
  14. 4.3.1 Kaifeng Mingren Pharmaceutical Company Information
  15. 4.3.2 Kaifeng Mingren Pharmaceutical Business Overview
  16. 4.3.3 Kaifeng Mingren Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Kaifeng Mingren Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  18. 4.3.5 Kaifeng Mingren Pharmaceutical Recent Developments
  19. 4.4 China Res Double-Crane
  20. 4.4.1 China Res Double-Crane Company Information
  21. 4.4.2 China Res Double-Crane Business Overview
  22. 4.4.3 China Res Double-Crane Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 China Res Double-Crane Vidarabine Monophosphate for Injection Product Portfolio
  24. 4.4.5 China Res Double-Crane Recent Developments
  25. 4.5 Hainan Jinrui Pharmaceutical
  26. 4.5.1 Hainan Jinrui Pharmaceutical Company Information
  27. 4.5.2 Hainan Jinrui Pharmaceutical Business Overview
  28. 4.5.3 Hainan Jinrui Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hainan Jinrui Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  30. 4.5.5 Hainan Jinrui Pharmaceutical Recent Developments
  31. 4.6 Hainan Huluwa Pharmaceutical Group
  32. 4.6.1 Hainan Huluwa Pharmaceutical Group Company Information
  33. 4.6.2 Hainan Huluwa Pharmaceutical Group Business Overview
  34. 4.6.3 Hainan Huluwa Pharmaceutical Group Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Hainan Huluwa Pharmaceutical Group Vidarabine Monophosphate for Injection Product Portfolio
  36. 4.6.5 Hainan Huluwa Pharmaceutical Group Recent Developments
  37. 4.7 Haikou Qili Pharmaceutical
  38. 4.7.1 Haikou Qili Pharmaceutical Company Information
  39. 4.7.2 Haikou Qili Pharmaceutical Business Overview
  40. 4.7.3 Haikou Qili Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Haikou Qili Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  42. 4.7.5 Haikou Qili Pharmaceutical Recent Developments
  43. 4.8 Sinopharm A-think Pharmaceutical
  44. 4.8.1 Sinopharm A-think Pharmaceutical Company Information
  45. 4.8.2 Sinopharm A-think Pharmaceutical Business Overview
  46. 4.8.3 Sinopharm A-think Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sinopharm A-think Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  48. 4.8.5 Sinopharm A-think Pharmaceutical Recent Developments
  49. 4.9 Guangdong Xianqiang Pharmaceutical
  50. 4.9.1 Guangdong Xianqiang Pharmaceutical Company Information
  51. 4.9.2 Guangdong Xianqiang Pharmaceutical Business Overview
  52. 4.9.3 Guangdong Xianqiang Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Guangdong Xianqiang Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  54. 4.9.5 Guangdong Xianqiang Pharmaceutical Recent Developments
  55. 4.10 Guangdong LongFu Medicine
  56. 4.10.1 Guangdong LongFu Medicine Company Information
  57. 4.10.2 Guangdong LongFu Medicine Business Overview
  58. 4.10.3 Guangdong LongFu Medicine Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Guangdong LongFu Medicine Vidarabine Monophosphate for Injection Product Portfolio
  60. 4.10.5 Guangdong LongFu Medicine Recent Developments
  61. 4.11 Gansu Changee Bio-pharmaceutical
  62. 4.11.1 Gansu Changee Bio-pharmaceutical Company Information
  63. 4.11.2 Gansu Changee Bio-pharmaceutical Business Overview
  64. 4.11.3 Gansu Changee Bio-pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Gansu Changee Bio-pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  66. 4.11.5 Gansu Changee Bio-pharmaceutical Recent Developments
  67. 4.12 FUREN Group Pharmaceutical
  68. 4.12.1 FUREN Group Pharmaceutical Company Information
  69. 4.12.2 FUREN Group Pharmaceutical Business Overview
  70. 4.12.3 FUREN Group Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 FUREN Group Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  72. 4.12.5 FUREN Group Pharmaceutical Recent Developments
  73. 4.13 Datong Wuzhou Tong Pharmaceutical
  74. 4.13.1 Datong Wuzhou Tong Pharmaceutical Company Information
  75. 4.13.2 Datong Wuzhou Tong Pharmaceutical Business Overview
  76. 4.13.3 Datong Wuzhou Tong Pharmaceutical Vidarabine Monophosphate for Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Datong Wuzhou Tong Pharmaceutical Vidarabine Monophosphate for Injection Product Portfolio
  78. 4.13.5 Datong Wuzhou Tong Pharmaceutical Recent Developments
5 Global Vidarabine Monophosphate for Injection Market Scenario by Region
  1. 5.1 Global Vidarabine Monophosphate for Injection Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vidarabine Monophosphate for Injection Sales by Region: 2021-2032
  3. 5.2.1 Global Vidarabine Monophosphate for Injection Sales by Region: 2021-2026
  4. 5.2.2 Global Vidarabine Monophosphate for Injection Sales by Region: 2027-2032
  5. 5.3 Global Vidarabine Monophosphate for Injection Revenue by Region: 2021-2032
  6. 5.3.1 Global Vidarabine Monophosphate for Injection Revenue by Region: 2021-2026
  7. 5.3.2 Global Vidarabine Monophosphate for Injection Revenue by Region: 2027-2032
  8. 5.4 North America Vidarabine Monophosphate for Injection Market Facts & Figures by Country
  9. 5.4.1 North America Vidarabine Monophosphate for Injection Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Vidarabine Monophosphate for Injection Sales by Country (2021-2032)
  11. 5.4.3 North America Vidarabine Monophosphate for Injection Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Vidarabine Monophosphate for Injection Market Facts & Figures by Country
  16. 5.5.1 Europe Vidarabine Monophosphate for Injection Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Vidarabine Monophosphate for Injection Sales by Country (2021-2032)
  18. 5.5.3 Europe Vidarabine Monophosphate for Injection Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Vidarabine Monophosphate for Injection Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Vidarabine Monophosphate for Injection Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Vidarabine Monophosphate for Injection Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Vidarabine Monophosphate for Injection Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Vidarabine Monophosphate for Injection Market Facts & Figures by Country
  41. 5.7.1 South America Vidarabine Monophosphate for Injection Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Vidarabine Monophosphate for Injection Sales by Country (2021-2032)
  43. 5.7.3 South America Vidarabine Monophosphate for Injection Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Vidarabine Monophosphate for Injection Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Vidarabine Monophosphate for Injection Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Vidarabine Monophosphate for Injection Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Vidarabine Monophosphate for Injection Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Vidarabine Monophosphate for Injection Sales by Type (2021-2032)
  2. 6.1.1 Global Vidarabine Monophosphate for Injection Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Vidarabine Monophosphate for Injection Sales Market Share by Type (2021-2032)
  4. 6.2 Global Vidarabine Monophosphate for Injection Revenue by Type (2021-2032)
  5. 6.2.1 Global Vidarabine Monophosphate for Injection Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Vidarabine Monophosphate for Injection Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Vidarabine Monophosphate for Injection Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Vidarabine Monophosphate for Injection Sales by Application (2021-2032)
  2. 7.1.1 Global Vidarabine Monophosphate for Injection Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Vidarabine Monophosphate for Injection Sales Market Share by Application (2021-2032)
  4. 7.2 Global Vidarabine Monophosphate for Injection Revenue by Application (2021-2032)
  5. 7.2.1 Global Vidarabine Monophosphate for Injection Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vidarabine Monophosphate for Injection Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Vidarabine Monophosphate for Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Vidarabine Monophosphate for Injection Value Chain Analysis
  2. 8.1.1 Vidarabine Monophosphate for Injection Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Vidarabine Monophosphate for Injection Production Mode & Process
  5. 8.2 Vidarabine Monophosphate for Injection Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Vidarabine Monophosphate for Injection Distributors
  8. 8.2.3 Vidarabine Monophosphate for Injection Customers
9 Global Vidarabine Monophosphate for Injection Analyzing Market Dynamics
  1. 9.1 Vidarabine Monophosphate for Injection Industry Trends
  2. 9.2 Vidarabine Monophosphate for Injection Industry Drivers
  3. 9.3 Vidarabine Monophosphate for Injection Industry Opportunities and Challenges
  4. 9.4 Vidarabine Monophosphate for Injection Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst